Checkpoint Therapeutics Overview

  • Founded
  • 2014
Founded
  • Status
  • Public
  • Employees
  • 8
Employees
  • Stock Symbol
  • CKPT
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $3.62
  • (As of Friday Closing)

Checkpoint Therapeutics General Information

Description

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 2 Gansevoort Street
  • 9th Floor
  • New York, NY 10014
  • United States
+1 (781) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Checkpoint Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.62 $3.73 $1.05 - $4.50 $246M 67.9M 681K -$0.46

Checkpoint Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 159,020 79,166 32,365 75,553
Revenue 1,067 1,708 3,506 1,725
EBITDA (21,816) (24,850) (36,515) (22,775)
Net Income (21,682) (24,714) (36,367) (22,677)
Total Assets 42,645 26,966 24,899 21,413
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Checkpoint Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Checkpoint Therapeutics‘s full profile, request access.

Request a free trial

Checkpoint Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisiti
Biotechnology
New York, NY
8 As of 2019
00000
00000000 00000

000000

quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000 000000000
Wilmington, DE
0000 As of 0000
00000000000

00000000

uat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pa
000000000000000
West Conshohocken, PA
00 As of 0000
000.00
000000 - 000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Checkpoint Therapeutics Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Incyte Corporate Backed or Acquired Wilmington, DE 0000 00000000000
00000000 000000000 Corporation West Conshohocken, PA 00 000.00 000000 - 000 000.00
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000 00000
000000000 00000000 Venture Capital-Backed Pittsburgh, PA 00 000.00 0000000000 000.00
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
You’re viewing 5 of 9 competitors. Get the full list »

Checkpoint Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
James Oliviero III Chief Executive Officer & Board Member
Garrett Gray Vice President, Finance and Accounting and Principal Financial Officer
David Horin Interim Chief Financial Officer
To view Checkpoint Therapeutics’s complete executive team members history, request access »

Checkpoint Therapeutics Board Members (1)

Name Representing Role Since
00000 00000000 000 Checkpoint Therapeutics Chief Executive Officer & Board Member 000 0000
To view Checkpoint Therapeutics’s complete board members history, request access »

Checkpoint Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Checkpoint Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 (0000000 000000000 00000 00 Buildings and Property
To view Checkpoint Therapeutics’s complete investments history, request access »